PMID- 26905220
OWN - NLM
STAT- MEDLINE
DCOM- 20160823
LR  - 20181113
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 16
DP  - 2016 Feb 13
TI  - Can BNP-guided therapy improve health-related quality of life, and do responders 
      to BNP-guided heart failure treatment have improved health-related quality of 
      life? Results from the UPSTEP study.
PG  - 39
LID - 10.1186/s12872-016-0221-7 [doi]
LID - 39
AB  - BACKGROUND: To investigate whether B-type natriuretic peptide (NP)-guided 
      treatment of heart failure (HF) patients improved their health related quality of 
      life (Hr-QoL) compared to routine HF treatment, and whether changes in Hr-QoL 
      differed depending on whether the patient was a responder to NP-guided therapy or 
      not. METHODS: A secondary analysis of the UPSTEP-study, a Scandinavian 
      multicentre study using a prospective, randomized, open, blinded evaluation 
      design on patients with HF with New York Heart Association (NYHA) class II-IV. 
      NP-guiding was aimed to reduce BNP <150 ng/L if < 75 years or BNP < 300 ng/L if > 
      75 years. A responder was defined as a patient with a BNP < 300 ng/L and/or a 
      decrease in BNP of at least 40% in week 16 compared to study start. Short form-36 
      (SF-36) was used to measure Hr-QoL. At the study start, 258 patients presented 
      evaluable SF-36 questionnaires, 131 in the BNP group and 127 in the control 
      group. At the study end 100 patients in the NP-guided group and 98 in the control 
      group, presenting data from both the study start and the study end. RESULTS: 
      There were no significant differences in Hr-QoL between NP-guided HF treatment 
      and control group; however significant improvements could be seen in four of the 
      eight domains in the NP-guided group, whereas in the control group improvements 
      could be seen in six of the domains. Among the responders improvements could be 
      noted in four domains whereas in the non-responders improvements could be seen in 
      only one domain evaluating within group changes. CONCLUSIONS: Improved Hr-QoL 
      could be demonstrated in several of the domains in both the NP-guided and the 
      control group. In the responder group within group analyses showed more increased 
      Hr-QoL compared to the non-responder group. However, all groups demonstrated 
      increase in Hr-QoL.
FAU - Karlstrom, Patric
AU  - Karlstrom P
AD  - Department of Medicine, Division of Cardiology, County Hospital Ryhov, Jonkoping, 
      Sweden. patric.karlstrom@rjl.se.
FAU - Johansson, Peter
AU  - Johansson P
AD  - Department of Cardiology and Department of Medical and Health Sciences, Linkoping 
      University, Linkoping, Sweden.
FAU - Dahlstrom, Ulf
AU  - Dahlstrom U
AD  - Department of Cardiology and Department of Medical and Health Sciences, Linkoping 
      University, Linkoping, Sweden.
FAU - Boman, Kurt
AU  - Boman K
AD  - Research unit Skelleftea Department of Medicine, Institution of Public Health and 
      Clinical Medicine, Umea University, Umea, Sweden.
FAU - Alehagen, Urban
AU  - Alehagen U
AD  - Department of Cardiology and Department of Medical and Health Sciences, Linkoping 
      University, Linkoping, Sweden.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160213
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin Receptor Antagonists/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Female
MH  - *Health Status
MH  - Heart Failure/blood/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/*therapeutic use
MH  - Natriuretic Peptide, Brain/*blood
MH  - Patient Care Planning
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC4763442
EDAT- 2016/02/26 06:00
MHDA- 2016/08/24 06:00
PMCR- 2016/02/13
CRDT- 2016/02/25 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/02/25 06:00 [entrez]
PHST- 2016/02/26 06:00 [pubmed]
PHST- 2016/08/24 06:00 [medline]
PHST- 2016/02/13 00:00 [pmc-release]
AID - 10.1186/s12872-016-0221-7 [pii]
AID - 221 [pii]
AID - 10.1186/s12872-016-0221-7 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2016 Feb 13;16:39. doi: 10.1186/s12872-016-0221-7.